AbbVie's JAK Inhibitor Key Global Phase 3 Results Announced for Treatment of Atopic Dermatitis

Article source: Pharmaceutical Guanlan

Recently, AbbVie (AbbVie) announced that the "Lancet" magazine published its JAK inhibitor upatinib for the critical global phase 3 clinical study of moderate to severe atopic dermatitis-Measure Up 1, Measure Up 2 And the main analysis results of AD Up.

Rinvoq (upadacitinib) was discovered and developed by AbbVie scientists.

According to the press release, the research published in The Lancet this time mainly evaluates the application of upatinib in adults and adolescents with moderate to severe atopic dermatitis who are suitable for systemic treatment.

The results showed that in all three studies, compared with placebo, upatinib showed significantly improved skin clearance and reduction of itching in adults and adolescents with moderate to severe atopic dermatitis.

In the above three key phase 3 studies of atopic dermatitis, the safety characteristics of upatinib are consistent.

Dr.

Previously, upatinib had also obtained positive results in a study called Heads Up, which allowed it to harvest powerful head-to-head clinical data in the field of atopic dermatitis.

In December 2020, AbbVie announced the main results of the Heads Up study: in the treatment of adult patients with moderate to severe atopic dermatitis, upatinib reached the primary endpoint of superiority relative to the control drug.

Atopic dermatitis is a chronic, recurrent, inflammatory skin disease.

Note: The original text has been deleted

Reference materials:

[1]Guttman-Yassky E.

[2]Reich K.